Results 11 to 20 of about 53,476 (305)
Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. [PDF]
PLoS ONE, 2017 Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis.
Lena Tschiderer +4 more
doaj +2 more sources
Journal of Extracellular Vesicles, 2021 Osteoporosis is one of the most common skeletal disorders caused by the imbalance between bone formation and resorption, resulting in quantitative loss of bone tissue.
Kyoung Soo Lee +15 more
doaj +2 more sources
Osteoprotegerin reduces osteoclast resorption activity without affecting osteogenesis on nanoparticulate mineralized collagen scaffolds. [PDF]
Science Advances, 2019 The instructive capabilities of extracellular matrix-inspired materials for osteoprogenitor differentiation have sparked interest in understanding modulation of other cell types within the bone regenerative microenvironment.
Bischoff, David +11 more
core +2 more sources
Osteoprotegerin in cardiometabolic disorders. [PDF]
International Journal of Endocrinology, 2015 Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such OPG
Lawrie, A. +2 more
core +9 more sources
Osteoprotegerin mediates tumor-promoting effects of Interleukin-1beta in breast cancer cells [PDF]
Molecular Cancer, 2017 __Background:__ It is widely recognized that inflammation promotes breast cancer invasion and metastasis. Given the complex nature of the breast tumor inflammatory microenvironment, much remains to be understood of the molecular mechanisms that govern ...
Chung, S.T.M. (Stephanie Tsang Mui) +4 more
core +4 more sources
Therapeutic implications of osteoprotegerin [PDF]
Cancer Cell International, 2009 Osteoprotegerin (OPG), a member of the tumor necrosis factor (TNF) receptor superfamily, contributes determinatively to the bone remodeling as well as to the pathogenetic mechanism of bone malignancies and disorders of mineral metabolism. There is additional evidence that OPG can promote cell survival by inhibiting TNF-related apoptosis-inducing ligand
Sofia Fili +2 more
openalex +5 more sources
Science Advances, 2023 Treatment for type 1 diabetes (T1D) requires stimulation of functional β cell regeneration and survival under stress. Previously, we showed that inhibition of the RANKL/RANK [receptor activator of nuclear factor kappa Β (NF-κB) ligand] pathway, by ...
N. G. Kondegowda +11 more
semanticscholar +1 more source
Diabetes/Metabolism Research Reviews, 2023 Novel biomarkers of vascular disease in diabetes could help identify new mechanistic pathways. Osteocalcin, osteoprotegerin, and osteopontin are key molecules involved in bone and vascular calcification processes, both of which are compromised in ...
E. Maddaloni +19 more
semanticscholar +1 more source
The roles of osteoprotegerin in cancer, far beyond a bone player
Cell Death Discovery, 2022 Osteoprotegerin (OPG), also known as tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a member of the tumor necrosis factor (TNF) receptor superfamily.
Yufei Wang +4 more
semanticscholar +1 more source
Stroke, 2022 Background: Osteoprotegerin was implicated in vascular injury and inflammatory responses, but its prognostic value in ischemic stroke remained unclear.
Zhengbao Zhu +11 more
semanticscholar +1 more source